Safranal

Research use only, not for human use.

Safranal is the special volatile aroma compound of saffron.Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research.

Safranal is the special volatile aroma compound of saffron.Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research.(In Vitro):At first, the potential toxic effect of safranal on OLN-93 viability was evaluated. Also, the cells were pretreated with safranal (0.1, 1, 10, 50, 100 and 200 μM) for 2 h and then subjected to glutamic acid (16 mM) or quinolinic acid (8 mM) toxicity for 24 h, in which the same treatments were applied. Results: Safranal at concentration ranges of 1-800 μM had no toxic effect on cell viability (p>0.05). Treatment with safranal significantly increased cell viability following glutamic acid or quinolinic acid insults at concentrations higher than 1 μM (p<0.01). The cytoprotective potential of safranal was also accompanied by decreased ROS accumulation (p<0.001) and malondialdehyde level (p<0.001) following glutamic acid or quinolinic acid insults. The data suggests that safranal exhibits oligoprotection potential by means of inhibiting oxidative stress parameters.(In Vivo):Safranal (200-500 mg/kg; PO; for 7 days) causes a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low.

Safranal (10-50 μM; for 1 h) dose-dependently decreases LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs. Safranal (10-50 μM; for 1 h) inhibits cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Safranal (10, 50 μM; for 1 h followed by stimulation with 1 μg/ml of LPS for 30 min) inhibits the nuclear translocation of NF-κB and AP-1 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Western Blot Analysis Cell Line:RAW264.7 cells and bone marrow-derived macrophages (BMDMs) Concentration:10, 50 μM Incubation Time:For 1 h prior to lipopolysaccharide (LPS) stimulation (1 μg/ml)Result:Dose-dependently decreased LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs. Inhibited the phosphorylation of MAPK pathway proteins extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38. Inhibited NF-κB pathway proteins IKKα/β and IκBα and the degradation of IκBα.RT-PCR Cell Line:RAW 264.7 cellsConcentration:10, 50 μM Incubation Time:For 1 h followed by stimulation with LPS (1 μg/ml) for 24 h Result:Inhibited cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.

Safranal (200-500 mg/kg; PO; for 7 days) causes a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low. Animal Model:Female BALB/c mice (18-20 g) (DSS-induced colitis mice) Dosage:200, 500 mg/kg Administration:PO; for 7 days Result:Caused a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low.

——

Others

Antioxidant

Antioxidant

——

——

116-26-7

150.221

C10H14O

>98% (HPLC)

In Vitro:?Ethanol : 100 mg/mL (665.69 m)

CC1=C(C=O)C(C)(C)CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years